实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (2): 248-251.doi: 10.3969/j.issn.1672-5069.2019.02.024

• 肝癌 • 上一篇    下一篇

肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨*

王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜   

  1. 014030 内蒙古自治区包头市肿瘤医院检验科(王虎明,周宁,丽敏,包娜娜);
    外科(徐杰,刘险峰);
    内蒙古医科大学第二附属医院外科(樊东升)
  • 收稿日期:2018-05-22 出版日期:2019-03-10 发布日期:2019-03-19

Cancerous miRNA-30c levels affecting the survival of patients with hepatocellular carcinoma after hepatectomy

Wang Huming, Fan Dongsheng, Xu Jie, Liu Xianfegn, Zhou Ning, Li Min, Bao Nana   

  1. Clinical Laboratory,Tumor Hospital,Baotou 014030,Inner Mongolia Autonomous Region,China
  • Received:2018-05-22 Online:2019-03-10 Published:2019-03-19

摘要: 目的 探讨肝细胞癌(HCC)患者癌组织微小RNA(miRNA)-30c(miRNA-30c)水平变化及其与预后的关系。方法 2010年2月~2012年11月我院收治的HCC患者35例,经外科手术切除肿瘤获得癌组织标本。采用RT-PCR法检测癌组织miRNA-30c相对水平。不同临床和病理因素患者癌组织miRNA-30c水平高低的风险比(OR)和95%可信区间(CI)采用Logistic二项回归分析。采用Kaplan-Meier最小乘积法评价患者的生存率,不同miRNA-30c水平患者生存率的差异比较采用Log-Rank检验。结果 35例HCC患者癌组织miRNA-30c相对水平为0.6,95%CI为0.3~0.6,其中癌组织miRNA-30c相对水平低于0.6者13例,大于0.6者22例;不同性别、年龄、肿瘤大小、分化程度、TNM分期、有无肝炎病史和血清甲胎蛋白(AFP)水平高低患者癌组织miRNA-30c水平差异无统计学意义(P>0.05),但17例存在淋巴结转移患者癌组织miRNA-30c水平为(0.2±0.0),显著低于18例无淋巴结转移患者【(0.8±0.1),P<0.05】;调整后的风险比(OR)=5.4,95%CI:1.2~20.1;癌组织miRNA-30c高水平患者总生存期为(14.5±6.7)个月,95%CI为11.0~28.4个月,显著长于低水平患者【(7.9±1.5)个月,95%CI为3.2~10.7个月,P<0.05】。结论 本研究结果表明,HCC患者癌组织miRNA-30c相对水平与患者预后有关,其是否可作为潜在的PLC诊断和预后判断的生物学标志物还需进一步研究。

关键词: 肝细胞癌, 微小RNA, 病理学, 预后

Abstract: Objective To investigate the relationship between cancerous miRNA-30c levels and the survival of patients with hepatocellular caicinoma (HCC) after hepatectomy. Methods Thirty-five patients with HCC in our hospital between February 2010 and November 2012 were included in this study. All patients were confirmed by pathological examination after hepatectomy,and cancerous miRNA-30c levels were assayed by real-time quantitative polymerase chain reaction. Cancerous miRNA-30c levels were compared between patients with different clinical and pathological features. The survival rate of patients was evaluated by the Kaplan-Meier minimum product method,and the difference of survival rate was evaluated by Log-Rank test. Results The relative level of cancerous miRNA-30c in the 35 patients with HCC was 0.6, with 95% CI of 0.3 to 0.6,and there were 13 patientss with low cancerous miRNA-30c level less than 0.6 and 22 patients with high cancerous miRNA-30c levels greater than 0.6;there were no significant differences of cancerous miRNA-30c levels between patients with diffenrent gender,age,tumor size,degree of differentiation,TNM staging,history of viral hepatitis,and serum AFP levels(P>0.05),however,the cancerous miRNA-30c levels in 17 patients with lymph node metastasis was(0.2±0.0),significantly lower than 【(0.8±0.1),P<0.05】 in 18 patients without lymph node matastasis;the adjusted risk ratio (OR)=5.4,and 95% CI:1.2 to 20.1;the total survival in patients with high cancerous miRNA-30c levels was (14.5±6.7) m,with 95%CI of 11.0-28.4 m,significantly longer than【(7.9±1.5) m,with 95%CI of 3.2-10.7 m,P<0.05】 in patients with lower cancerous miRNA-30c levels. Conclusion Our findings indicate that the cancerous miRNA-30c level is related to the prognosis of patients with hepatocellular carcinoma,and it might be a new potential biomarker for predicting the survival of patients with hepatocellular carcinoma after hepatectomy.

Key words: Hepatocellular carcinoma, micro RNA, Pathology, Prognosis